Verastem, Inc. (VSTM)
| Market Cap | 210.59M |
| Revenue (ttm) | 3.64M |
| Net Income (ttm) | -73.13M |
| Shares Out | 186.36M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,049,361 |
| Open | 1.14 |
| Previous Close | 1.16 |
| Day's Range | 1.09 - 1.22 |
| 52-Week Range | 1.00 - 3.96 |
| Beta | 0.89 |
| Analysts | Buy |
| Price Target | 5.36 (+374.3%) |
| Earnings Date | Aug 1, 2022 |
About VSTM
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination wi... [Read more...]
Financial Performance
In 2021, Verastem's revenue was $2.05 million, a decrease of -97.68% compared to the previous year's $88.52 million. Losses were -$71.20 million, 5.13% more than in 2020.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for VSTM stock is "Buy." The 12-month stock price forecast is 5.36, which is an increase of 374.34% from the latest price.
News
3 Top Penny Stocks to Add to Your July 2022 Watchlist
Here's three penny stocks to watch in July 2022 The post 3 Top Penny Stocks to Add to Your July 2022 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm
With the anticipation of a 2Q program update, Verastem Oncology (NASDAQ: VSTM) announced that its interim analysis findings for the RAMP 201 program for recurrent low-grade serous ovarian cancer (LGSOC)...
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for people living with cancer, today announced an update from an interim analy...
Best Penny Stocks to Buy in June 2022? 3 to Watch This Week
Check these penny stocks out for your June watchlist The post Best Penny Stocks to Buy in June 2022? 3 to Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks...
Verastem Oncology Awarded Pancreatic Cancer Action Network's First Therapeutic Accelerator Award to Evaluate the Comb...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has received the first “Ther...
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three month...
3 Penny Stocks to Watch With Above Average Volume Today
Are these high-volume penny stocks on your buy list right now? The post 3 Penny Stocks to Watch With Above Average Volume Today appeared first on Penny Stocks to Buy, Picks, News and Information | Penn...
Top Penny Stocks Under $2 to Watch As Inflation Rises
Here are three penny stocks under $2 to watch right now The post Top Penny Stocks Under $2 to Watch As Inflation Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchas...
Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development
Verastem Oncology Inc (NASDAQ: VSTM) entered into a credit facility with Oxford Finance LLC for up to $150 million to primarily support the continued development, commercial preparation, and potential l...
Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three month...
Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tu...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced it has entered into a credit facilit...
Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that Channing Der, PhD, has been ...
Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why
Truist has initiated coverage on Verastem Oncology Inc (NASDAQ: VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst Srikripa Devarakonda notes that trading a...
Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone o...
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today outlined key strategic priorities and upcom...
Verastem Oncology to Participate in Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will participate...
Mirati (MRTX), Verastem to Study Cancer Drugs for NSCLC
Mirati Therapeutics (MRTX) partners Verastem Oncology (VSTM) to evaluate adagrasib in combination with VS-6766 in KRASG12C-mutant non-small cell lung cancer.
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutan...
SAN DIEGO and BOSTON, Nov. 22, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq:MRTX), a clinical-stage targeted oncology company and Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company c...
Verastem Oncology to Present at the Jefferies London Healthcare Conference
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at ...
Verastem Oncology Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three month...
Verastem Oncology Appoints Michelle Robertson to Board of Directors
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of Michelle Rober...
3 Biotech Stocks That Could Make You Filthy Rich
These three low-priced cancer stocks could be grossly undervalued.
Top Penny Stocks To Buy The Dip According To Analysts In September
Analysts say these are penny stocks to buy right now. The post Top Penny Stocks To Buy The Dip According To Analysts In September appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...
Verastem Oncology Appoints Louis J. Denis, M.D.
BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Louis J. Denis, M....